US reclassifies cannabis as Schedule III, exposing racial disparities in drug policy and corporate capture of reform

Indigenous and traditional knowledge systems have long recognized cannabis as a medicinal and spiritual plant, with uses documented in Ayurvedic, African, and Native American traditions. The criminalization of cannabis in the 20th century was a colonial disruption of these practices, often enforced through racist drug policies that targeted marginalized communities. Modern reclassification efforts in the US and Canada still prioritize Western biomedical frameworks, sidelining Indigenous knowledge systems and healing practices. The lack of consultation with Indigenous communities in policy reform reflects a systemic erasure of their expertise and sovereignty over plant medicines.

The reclassification of cannabis from Schedule I to Schedule III marks the first major federal policy shift since the 1970 Controlled Substances Act, which classified cannabis alongside heroin. This Act was shaped by racist narratives linking cannabis to Mexican immigrants and Black communities, as well as corporate interests in suppressing hemp competition. Historical parallels include the 2018 Farm Bill's legalization of hemp, which was also driven by corporate lobbying and failed to address racial disparities in enforcement. The US is following a global trend of incremental reform, but these changes often obscure the persistent criminalization of marginalized groups under new legal frameworks.

Globally, cannabis policies vary widely, with countries like Portugal decriminalizing all drugs in 2001 and seeing significant reductions in overdose deaths and HIV transmission. In contrast, countries like the Philippines and Indonesia maintain punitive approaches, often tied to authoritarian regimes. In Africa, cannabis is both a traditional medicine and a cash crop, yet many governments enforce colonial-era laws that criminalize its use. The US reclassification reflects a neoliberal approach to drug policy, prioritizing market-based solutions over public health or social justice models seen in other cultures.

Scientific consensus supports the reclassification of cannabis as less harmful than Schedule I substances, given its lower potential for addiction and overdose compared to opioids or stimulants. Studies show that Schedule III classification aligns with evidence that cannabis has medical benefits, particularly for chronic pain, epilepsy, and nausea. However, the DEA's decision is also influenced by pharmaceutical industry lobbying, which seeks to monopolize cannabis-based medicines. The lack of comprehensive clinical trials on cannabis is partly due to its Schedule I status, which has historically restricted research funding and access to samples.

Cannabis has been a sacred plant in many spiritual traditions, from the Hindu use of bhang to the Rastafarian sacrament of ganja, symbolizing connection to the divine and communal healing. Artists and musicians, particularly in the jazz and reggae traditions, have long used cannabis as a tool for creativity and resistance against oppressive systems. The criminalization of cannabis was also an attack on these cultural expressions, with jazz musicians like Louis Armstrong facing surveillance and arrest. Modern reclassification efforts often strip cannabis of its spiritual and cultural significance, reducing it to a commodity for corporate exploitation.

The reclassification could lead to increased corporate investment in cannabis-based pharmaceuticals, potentially sidelining small farmers and Indigenous knowledge holders. It may also normalize cannabis use in a way that increases consumption among youth, despite evidence of harms to developing brains. Future scenarios include a bifurcated market where corporate cannabis products dominate, while marginalized communities continue to face criminalization under Schedule III. Global implications could include pressure on other countries to follow the US model, despite evidence that decriminalization and harm reduction approaches yield better public health outcomes.

Black and Latino communities have been disproportionately targeted by cannabis prohibition, with arrest rates up to 10 times higher than white communities despite similar usage rates. The reclassification does not address the 40,000+ individuals still incarcerated for cannabis offenses, nor does it mandate expungement of past convictions. Social equity programs in states like California and Illinois have struggled to provide equitable access to licenses for marginalized entrepreneurs, often due to corporate lobbying and bureaucratic barriers. The voices of affected communities, including those who have lost family members to the War on Drugs, are largely absent from mainstream narratives about cannabis reform.